The Trump administration’s move to pause federal funding while projects are vetted causes concern and lawsuits

What can we expect the US life sciences sector to look like over the course of the next four years as Donald Trump takes up his presidency?

Watch our video interview covering Claus Zieler’s career and passion for improving investment in Europe.

Why mRNA will be a key disrupter in the coming years; experts from CureVac and Omega Therapeutics give their views.

How understanding and manipulating senescence dynamics could optimize cancer therapies and improve patient outcomes.

Welcome back to our interview series with Jon Thomas, President and CEO of the California Institute for Regenerative Medicine: CIRM.

How can you ensure your gene therapy research won’t be slowed down by synthesis problems?

Who will be the grand winner of our 2024 Innovation Awards?

Sitting Down With… Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult.

How unified assay protocols and advanced bioinformatics are refining our understanding of mitochondrial dysfunction in complex diseases.